IN A NUTSHELL:
Leading psychopharmacologist Roland Griffiths discloses the ways that psychedelic drugs can be used to create spiritually meaningful, personally transformative experiences for all patients, especially the terminally ill.
Forty years after the Nixon administration effectively shut down research on psychedelic drugs, Roland Griffiths helped reopen it. One of the nation’s leading psychopharmacologists, Griffiths’ research focuses on the behavioral and subjective effects of mood-altering drugs. He is the lead investigator of the Psilocybin Research Initiative at Johns Hopkins, which includes studies of psilocybin occasioned mystical experience in healthy volunteers and cancer patients, and a pilot study of psilocybin-facilitated smoking cessation. Roland is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. He has been a consultant to the National Institutes of Health, and to numerous pharmaceutical companies in the development of new psychotropic drugs.
Taking a new look at psychedelics: Q&A with Roland Griffiths
The Trip Treatment
Pollan, M. The New Yorker Magazine. 2015.
Mills, A. Radiolab. 2014.
Mystical Experiences of Psilocybin
Griffiths, R. TEDxMidAtlantic. 2009
Johns Hopkins Medicine. 2006.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths R, Richards WA, McCann U, Jesse R. Psychopharmacology. 2006;187(3):268-283.
A Collection of Johns Hopkins Psilocybin Publications
Council on Spiritual Practices.
Religious Leaders Study
Johns Hopkins Medicine. 2016.
Hopkins Long-Term Meditator Study
Johns Hopkins Medicine. 2013.
Spiritual Psilocybin Researcher